von Hippel-Lindau tumour suppressor
Last updated 8 May 2023
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
The VHL gene provides instructions for making a protein that functions as part of a complex (a group of proteins that work together) called the VCB-CUL2 complex. This complex targets other proteins to be broken down (degraded) by the cell when they are no longer needed. Protein degradation is a normal process that removes damaged or unnecessary proteins and helps maintain the normal functions of cells.
Video picks for GenesVideo library
Normal function
The VHL gene provides instructions for making a protein that functions as part of a complex (a group of proteins that work together) called the VCB-CUL2 complex. This complex targets other proteins to be broken down (degraded) by the cell when they are no longer needed. Protein degradation is a normal process that removes damaged or unnecessary proteins and helps maintain the normal functions of cells.
One of the targets of the VCB-CUL2 complex is a protein called hypoxia-inducible factor 2-alpha (HIF-2α). HIF-2α is one part (subunit) of a larger protein complex called HIF, which plays a critical role in the body's ability to adapt to changing oxygen levels. HIF controls several genes involved in cell division, the formation of new blood vessels, and the production of red blood cells. It is the major regulator of a hormone called erythropoietin, which controls red blood cell production. HIF's function is particularly important when oxygen levels are lower than normal (hypoxia). However, when adequate oxygen is available, the VCB-CUL2 complex keeps HIF from building up inappropriately in cells.
The VHL protein likely plays a role in other cellular functions, including the regulation of other genes and control of cell division. Based on this function, the VHL protein is classified as a tumour suppressor, which means it prevents cells from growing and dividing too rapidly or in an uncontrolled way. The VHL protein is also involved in the formation of the extracellular matrix, which is an intricate lattice that forms in the spaces between cells and provides structural support to tissues.
Conditions referring to this gene or chromosome
Other names
pVHL
VHL1
VHL_HUMAN
Patient picks for Genes

Cancer
Brain tumours
This leaflet aims to give a brief overview of the various types of brain tumours. The treatment and survival rates vary greatly, depending on factors such as the type of tumour and the location in the brain.
by Dr Toni Hazell, FRCGP

Cancer
Wilms' tumour
A Wilms' tumour is a type of kidney cancer that usually affects young children. Wilms' tumours can appear in older children and adults but this is very rare. A Wilms' tumour is also known as a nephroblastoma Wilm's tumour is the most common type of kidney cancer in children but is very rare. About 80 children are diagnosed with a Wilms' tumour each year in the UK. The most common symptom is a swollen tummy (abdomen). The treatment for Wilms' tumour usually includes surgery and may also include chemotherapy and radiotherapy. The outcome (prognosis) for Wilms' tumour is usually very good for all children with a Wilms' tumour. Most children diagnosed with Wilms' tumour will survive long-term.
by Dr Colin Tidy, MRCGP

Gynaecological cancer
What does the cervical cancer jab do?
Dr Sarah Jarvis MBE Treatment options which may be considered include surgery, radiotherapy, chemotherapy or a combination of these treatments. The treatment advised for each case depends on various factors. For example, the stage of the cancer (how large the first (primary) cancer tumour is and whether it has spread), your general health and also if you are planning on having children. [https://patient.info/health/gynaecological-cancer/cervical-cancer](https://patient.info/health/gynaecological-cancer/cervical-cancer)
by Dr Sarah Jarvis

Pregnancy complications
Is a molar pregnancy a tumour?
Dr Sarah Jarvis MBE A hydatidiform mole is a growing mass of tissue inside your womb (uterus) that will not develop into a baby. It is the result of abnormal conception. It may cause bleeding in early pregnancy and is usually picked up in an early pregnancy ultrasound scan. For more information on molar pregnancy, go to [https://patient.info/health/hydatidiform-mole](https://patient.info/health/hydatidiform-mole)
by Dr Sarah Jarvis
Related patient information and medicines

Patient information leaflet
Kidney cancer
There are several types of kidney cancer but over 9 out of 10 kidney cancers are "renal cell cancer". This is sometimes called renal a... (A faulty gene which runs in some families may sometimes trigger kidney cancer. Also, people with some rare genetic disorders have a higher risk of developing kidney cancer - for example, von Hippel-Lindau.

Patient information leaflet
Stomach cancer
Most people who develop stomach cancer are over the age of 55. What are the types of stomach cancer. Adenocarcinoma of the stomach In most cases, stomach cancer begins from a cell ... For example, a blockage may be eased by removing part of the stomach, or by using laser surgery or by a bypass operation. Chemotherapy Chemotherapy is a treatment of.

Patient information leaflet
Headache
The most common types of headache are tension headaches and migraines. Treatment is with a course of steroids and they are typically needed for many months. Brain tumours Brain tumour Brain tumours is a very uncommon cause of headaches - although most patients with long-lasting, severe or persistent headaches start to worry that this may be the.

Patient information leaflet
Primary liver cancer
Many people who develop primary liver cancer will already have symptoms associated with scarring of the liver (cirrhosis). If you already have cirrhosis and your health becomes worse quite quickly, the cause may be a liver cancer which has developed. Everyone with cirrhosis should be having regular monitoring with an ultrasound and blood tests to.

Patient information leaflet
Acromegaly
This causes a range of symptoms that develop gradually, often over several years. The most noticeable symptoms are that your hands and feet become larger and features of your face may become more prominent. The cause is usually a small non-cancerous growth (tumour) in the pituitary gland. Treatment options include surgery to remove the growth and.

Patient information leaflet
Cushing's syndrome
Cushing's syndrome is caused by too high a level of glucocorticoid in the body. This can be caused by taking steroid medication long-term (the common cause) or by the body making too much cortisol (the main glucocorticoid made by the body). Symptoms usually develop gradually and so the diagnosis (other than that caused by steroid medication) may.
Further reading and references
- von Hippel-Lindau tumour suppressor; MedlinePlus, National Library of Medicine.
- Burnichon N, Vescovo L, Amar L, Libe R, de Reynies A, Venisse A, Jouanno E, Laurendeau I, Parfait B, Bertherat J, Plouin PF, Jeunemaitre X, Favier J, Gimenez-Roqueplo AP. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet. 2011 Oct 15;20(20):3974-85. doi: 10.1093/hmg/ddr324. Epub 2011 Jul 22.
- Kaelin WG Jr. The von hippel-lindau tumor suppressor protein: an update. Methods Enzymol. 2007;435:371-83. doi: 10.1016/S0076-6879(07)35019-2.
- Kaelin WG. Von Hippel-Lindau disease. Annu Rev Pathol. 2007;2:145-73. doi: 10.1146/annurev.pathol.2.010506.092049.
- Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004 Dec 15;22(24):4991-5004. doi: 10.1200/JCO.2004.05.061.
- Maranchie JK, Afonso A, Albert PS, Kalyandrug S, Phillips JL, Zhou S, Peterson J, Ghadimi BM, Hurley K, Riss J, Vasselli JR, Ried T, Zbar B, Choyke P, Walther MM, Klausner RD, Linehan WM. Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Hum Mutat. 2004 Jan;23(1):40-6. doi: 10.1002/humu.10302.
- McMullin MF. HIF pathway mutations and erythrocytosis. Expert Rev Hematol. 2010 Feb;3(1):93-101. doi: 10.1586/ehm.09.68.
- Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peczkowska M, Szmigielski C, Eng C; Freiburg-Warsaw-Columbus Pheochromocytoma Study Group. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002 May 9;346(19):1459-66. doi: 10.1056/NEJMoa020152.
- Pastore Y, Jedlickova K, Guan Y, Liu E, Fahner J, Hasle H, Prchal JF, Prchal JT. Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia. Am J Hum Genet. 2003 Aug;73(2):412-9. doi: 10.1086/377108. Epub 2003 Jul 3.
- Percy MJ, Rumi E. Genetic origins and clinical phenotype of familial and acquired erythrocytosis and thrombocytosis. Am J Hematol. 2009 Jan;84(1):46-54. doi: 10.1002/ajh.21313.
- Percy MJ. Genetically heterogeneous origins of idiopathic erythrocytosis. Hematology. 2007 Apr;12(2):131-9. doi: 10.1080/10245330601111979.
- Sufan RI, Jewett MA, Ohh M. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. Am J Physiol Renal Physiol. 2004 Jul;287(1):F1-6. doi: 10.1152/ajprenal.00424.2003.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

